Medications

MyAlli logo

alli is an over-the-counter orlistat 60 mg weight-loss aid for adults, used with a reduced-calorie, low-fat diet. MyAlli provides the official product information and…

September 24, 2026 7.9/10
Omada Health logo

Omada Health is a virtual, benefit-based health program. Its Prevention & Weight Health service combines a health coach, weekly learning, tracking tools and, for…

September 24, 2026 6.9/10
Parsley Health logo

Parsley Health provides functional and reproductive-health care, including clinician visits, diagnostic testing and nutrition coaching. Its fertility-related support sits within a broader membership and…

September 24, 2026 6.2/10
Reverse Health logo

Reverse Health is a subscription wellness app for women over 40, with meal plans, recipes, exercise videos and progress tools. Its terms say the…

September 24, 2026 6.8/10
Winona logo

Winona is a menopause-focused telehealth service offering prescription hormone therapy and non-hormonal options. It is not a weight-loss clinic and does not prescribe GLP-1…

September 24, 2026 5.9/10
Noom Med logo

Noom Med combines clinician-reviewed weight-care pathways with Noom’s behavior-change app, lessons and coaching. Its public pricing includes bundled self-pay plans and branded-prescription support; exact…

$39/mo 7.5/10
Mochi Health Review 2026: Real Cost, Compounded GLP-1s and Customer Ratings

Hims Weight Loss charges $39 for the first membership month, then $149/month, with medication billed separately. Its current public pages list FDA-approved Wegovy options…

$39/mo 6.9/10

Once-daily oral GLP-1 pill from Eli Lilly, FDA-approved April 1, 2026 for weight management in adults. Launch self-pay price from $149/month for the lowest…

September 20, 2026

Once-weekly tirzepatide injection from Eli Lilly, FDA-approved for type 2 diabetes. Not approved for weight management. Official self-pay price not publicly verified (Sept 20,…

September 20, 2026

Once-weekly tirzepatide injection from Eli Lilly, FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity. Self-pay $299 to $449/month via…

$299/mo

Once-weekly semaglutide injection from Novo Nordisk, FDA-approved for type 2 diabetes and related heart and kidney risk reduction. Not approved for weight management. Self-pay…

$349/mo

Once-daily oral semaglutide tablet from Novo Nordisk, FDA-approved December 2025 for weight management and cardiovascular risk reduction in adults. Self-pay $149 to $299/month by…

$149/mo